Literature DB >> 22521648

In vivo phage display to identify new human antibody fragments homing to atherosclerotic endothelial and subendothelial tissues [corrected].

Kamel Deramchia1, Marie-Josée Jacobin-Valat, Amélie Vallet, Hervé Bazin, Xavier Santarelli, Stéphane Sanchez, Pierre Dos Santos, Jean-Michel Franconi, Stéphane Claverol, Stéphane Bonetto, Gisèle Clofent-Sanchez.   

Abstract

In vivo phage display selection is a powerful strategy for directly identifying agents that target the vasculature of normal or diseased tissues in living animals. We describe here a new in vivo biopanning strategy in which a human phage single-chain antibody (scFv) library was injected into high-fat diet-fed ApoE(-/-) mice. Extracellular and internalized phage scFvs were selectively recovered from atherosclerotic vascular endothelium and subjacent tissues. After three successive biopanning rounds, a panel of six clones with distinct gene sequences was isolated. Four scFvs produced and purified in soluble form were shown to interact in vitro with a rabbit atheromatous protein extract by time-resolved fluorescence resonance energy transfer and to target the endothelial cell surface and inflamed intima-related regions of rabbit and human tissue sections ex vivo. These new scFvs selected in a mouse model recognized both rabbit and human tissue, underlying the interspecies similarities of the recognized epitopes. By combining immunoprecipitation and mass spectrometry, one of the selected scFvs was shown to recognize carbonic anhydrase II, an up-regulated enzyme involved in resorption of ectopic calcification. These results show that in vivo biopanning selection in hypercholesterolemic animals makes it possible to identify both scFvs homing to atherosclerotic endothelial and subendothelial tissues, and lesion-associated biomarkers. Such scFvs offer promising opportunities in the field of molecular targeting for the treatment of atherosclerosis.
Copyright © 2012 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22521648     DOI: 10.1016/j.ajpath.2012.02.013

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  15 in total

Review 1.  Selection strategies for anticancer antibody discovery: searching off the beaten path.

Authors:  David Sánchez-Martín; Morten Dræby Sørensen; Simon Lykkemark; Laura Sanz; Peter Kristensen; Erkki Ruoslahti; Luis Álvarez-Vallina
Journal:  Trends Biotechnol       Date:  2015-03-26       Impact factor: 19.536

2.  Selection of phage-displayed accessible recombinant targeted antibodies (SPARTA): methodology and applications.

Authors:  Sara D'Angelo; Fernanda I Staquicini; Fortunato Ferrara; Daniela I Staquicini; Geetanjali Sharma; Christy A Tarleton; Huynh Nguyen; Leslie A Naranjo; Richard L Sidman; Wadih Arap; Andrew Rm Bradbury; Renata Pasqualini
Journal:  JCI Insight       Date:  2018-05-03

3.  Ligand-directed targeting of lymphatic vessels uncovers mechanistic insights in melanoma metastasis.

Authors:  Dawn R Christianson; Andrey S Dobroff; Bettina Proneth; Amado J Zurita; Ahmad Salameh; Eleonora Dondossola; Jun Makino; Cristian G Bologa; Tracey L Smith; Virginia J Yao; Tiffany L Calderone; David J O'Connell; Tudor I Oprea; Kazunori Kataoka; Dolores J Cahill; Jeffrey E Gershenwald; Richard L Sidman; Wadih Arap; Renata Pasqualini
Journal:  Proc Natl Acad Sci U S A       Date:  2015-02-06       Impact factor: 11.205

Review 4.  Phage Display Libraries: From Binders to Targeted Drug Delivery and Human Therapeutics.

Authors:  Mouldy Sioud
Journal:  Mol Biotechnol       Date:  2019-04       Impact factor: 2.695

5.  Proteasome activator complex PA28 identified as an accessible target in prostate cancer by in vivo selection of human antibodies.

Authors:  David Sánchez-Martín; Jorge Martínez-Torrecuadrada; Tambet Teesalu; Kazuki N Sugahara; Ana Alvarez-Cienfuegos; Pilar Ximénez-Embún; Rodrigo Fernández-Periáñez; M Teresa Martín; Irene Molina-Privado; Isabel Ruppen-Cañás; Ana Blanco-Toribio; Marta Cañamero; Angel M Cuesta; Marta Compte; Leonor Kremer; Carmen Bellas; Vanesa Alonso-Camino; Irene Guijarro-Muñoz; Laura Sanz; Erkki Ruoslahti; Luis Alvarez-Vallina
Journal:  Proc Natl Acad Sci U S A       Date:  2013-08-05       Impact factor: 11.205

Review 6.  Current state of in vivo panning technologies: Designing specificity and affinity into the future of drug targeting.

Authors:  Heather H Gustafson; Audrey Olshefsky; Meilyn Sylvestre; Drew L Sellers; Suzie H Pun
Journal:  Adv Drug Deliv Rev       Date:  2018-06-28       Impact factor: 15.470

7.  Selection of scFv Antibody Fragments Binding to Human Blood versus Lymphatic Endothelial Surface Antigens by Direct Cell Phage Display.

Authors:  Thomas Keller; Romana Kalt; Ingrid Raab; Helga Schachner; Corina Mayrhofer; Dontscho Kerjaschki; Brigitte Hantusch
Journal:  PLoS One       Date:  2015-05-20       Impact factor: 3.240

8.  Discovery of novel peptides targeting pro-atherogenic endothelium in disturbed flow regions -Targeted siRNA delivery to pro-atherogenic endothelium in vivo.

Authors:  Jihwa Chung; Hyunbo Shim; Kwanchang Kim; Duhwan Lee; Won Jong Kim; Dong Hoon Kang; Sang Won Kang; Hanjoong Jo; Kihwan Kwon
Journal:  Sci Rep       Date:  2016-05-12       Impact factor: 4.379

Review 9.  Peptide and protein nanoparticle conjugates: versatile platforms for biomedical applications.

Authors:  Christopher D Spicer; Coline Jumeaux; Bakul Gupta; Molly M Stevens
Journal:  Chem Soc Rev       Date:  2018-05-21       Impact factor: 54.564

10.  By-passing large screening experiments using sequencing as a tool to identify scFv fragments targeting atherosclerotic lesions in a novel in vivo phage display selection.

Authors:  Kamel Deramchia; Marie-Josee Jacobin-Valat; Jeanny Laroche-Traineau; Stephane Bonetto; Stephane Sanchez; Pierre Dos Santos; Philippe Massot; Jean-Michel Franconi; Pierre Martineau; Gisele Clofent-Sanchez
Journal:  Int J Mol Sci       Date:  2012-06-07       Impact factor: 6.208

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.